INTERCEPT PHARMACEUTICALS IN's ticker is ICPT and the CUSIP is 45845P108. A total of 198 filers reported holding INTERCEPT PHARMACEUTICALS IN in Q3 2019. The put-call ratio across all filers is 1.15 and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $375,324 | +187.3% | 20,244 | +71.4% | 0.00% | +100.0% |
Q2 2023 | $130,630 | -17.6% | 11,811 | +0.1% | 0.00% | 0.0% |
Q1 2023 | $158,514 | +10.8% | 11,803 | +2.0% | 0.00% | 0.0% |
Q4 2022 | $143,096 | -11.7% | 11,568 | -0.4% | 0.00% | 0.0% |
Q3 2022 | $162,000 | +2.5% | 11,610 | +1.4% | 0.00% | 0.0% |
Q2 2022 | $158,000 | -21.8% | 11,446 | -7.7% | 0.00% | 0.0% |
Q1 2022 | $202,000 | -6.5% | 12,399 | -6.6% | 0.00% | 0.0% |
Q4 2021 | $216,000 | -5.3% | 13,271 | -13.5% | 0.00% | 0.0% |
Q3 2021 | $228,000 | -27.4% | 15,341 | -2.3% | 0.00% | 0.0% |
Q2 2021 | $314,000 | -10.0% | 15,706 | +3.9% | 0.00% | 0.0% |
Q1 2021 | $349,000 | -6.2% | 15,111 | +0.3% | 0.00% | 0.0% |
Q4 2020 | $372,000 | -42.1% | 15,071 | -2.8% | 0.00% | -66.7% |
Q3 2020 | $643,000 | -15.4% | 15,505 | -2.2% | 0.00% | -25.0% |
Q2 2020 | $760,000 | -19.0% | 15,857 | +6.5% | 0.00% | -20.0% |
Q1 2020 | $938,000 | -51.9% | 14,894 | -5.5% | 0.01% | -37.5% |
Q4 2019 | $1,952,000 | +85.2% | 15,755 | -0.8% | 0.01% | +100.0% |
Q3 2019 | $1,054,000 | -15.9% | 15,888 | +0.9% | 0.00% | -20.0% |
Q2 2019 | $1,253,000 | -19.8% | 15,744 | +12.7% | 0.01% | -16.7% |
Q1 2019 | $1,562,000 | +7.5% | 13,968 | -3.1% | 0.01% | 0.0% |
Q4 2018 | $1,453,000 | -20.9% | 14,421 | -0.8% | 0.01% | 0.0% |
Q3 2018 | $1,836,000 | +53.4% | 14,532 | +1.8% | 0.01% | +50.0% |
Q2 2018 | $1,197,000 | +4688.0% | 14,269 | +3388.8% | 0.00% | – |
Q1 2018 | $25,000 | 0.0% | 409 | -3.5% | 0.00% | – |
Q4 2017 | $25,000 | -52.8% | 424 | -2.3% | 0.00% | – |
Q2 2017 | $53,000 | +26.2% | 434 | +16.4% | 0.00% | – |
Q1 2017 | $42,000 | 0.0% | 373 | -3.6% | 0.00% | – |
Q4 2016 | $42,000 | -99.9% | 387 | 0.0% | 0.00% | – |
Q3 2016 | $63,696,000 | +10.5% | 387 | -4.2% | 0.00% | – |
Q2 2016 | $57,643,000 | -0.6% | 404 | -10.4% | 0.00% | – |
Q1 2016 | $58,000,000 | -15.9% | 451 | -2.0% | 0.00% | – |
Q4 2015 | $69,000,000 | +107712.5% | 460 | +19.8% | 0.00% | – |
Q3 2015 | $64,000 | -99.9% | 384 | +10.0% | 0.00% | – |
Q2 2015 | $84,242,000 | +3.0% | 349 | +20.3% | 0.00% | – |
Q1 2015 | $81,786,000 | +100.9% | 290 | +11.1% | 0.00% | – |
Q4 2014 | $40,716,000 | -29.5% | 261 | +7.0% | 0.00% | – |
Q3 2014 | $57,753,000 | +4.3% | 244 | +4.3% | 0.00% | – |
Q2 2014 | $55,371,000 | -96.6% | 234 | -95.2% | 0.00% | -100.0% |
Q1 2014 | $1,612,014,000 | +396.4% | 4,888 | +2.8% | 0.01% | +300.0% |
Q4 2013 | $324,740,000 | +11.8% | 4,756 | +13.0% | 0.00% | 0.0% |
Q3 2013 | $290,547,000 | +99.6% | 4,209 | +29.6% | 0.00% | +100.0% |
Q2 2013 | $145,595,000 | – | 3,247 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Sarissa Capital Management LP | 635,300 | $53,308,000 | 10.69% |
Senvest Management, LLC | 976,127 | $81,907,000 | 5.65% |
Melqart Asset Management (UK) Ltd | 390,600 | $32,775,000 | 2.80% |
Asymmetry Capital Management, L.P. | 25,918 | $2,175,000 | 2.14% |
Elk Creek Partners, LLC | 386,397 | $32,423,000 | 1.78% |
BB BIOTECH AG | 545,719 | $45,791,000 | 1.32% |
ALTRINSIC GLOBAL ADVISORS LLC | 383,166 | $32,151,000 | 1.27% |
DLD Asset Management, LP | 129,000 | $10,824,000 | 0.82% |
Opus Point Partners Management, LLC | 3,998 | $335,000 | 0.73% |
Virtus ETF Advisers LLC | 8,970 | $753,000 | 0.67% |